Investigation of the Lobular Carcinoma in Situ, Using Molecular Genetic Techniques, for the Involvement of Novel Genes
Abstract
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), i.e. lobular neoplasia (LN), are lesions of significance in terms of implication to the patient in the development of invasive carcinoma. A correlation between the lobular histological type and the inactivation of E-cadherin, a cell adhesion protein, has been reported. As well, mutations in CDHl have been reported in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC. Our study proposes to investigate LN lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins in order to characterize a profile for lobular neoplasia. We have obtained 22 LN cases (14 ALH and 14 LCIS lesions). LN cases have been found to be negative for E-cadherin (26/26), beta-catenin (25/26) and alpha-catenin (21/23) protein expression. CDHl alterations have been found to characterize LCIS lesions (14/14) but not ALH lesions (1/14). Moreover, LOH at the 16q locus was found to be an infrequent event (3/25). Studies are now in progress to evaluate p120-catenin protein expression, E-cadherin promoter methylation, and the involvement of novel genes at the stage of LN by CGH microarray. The completion of these analyses will provide insight into the molecular genetic profile for lobular neoplasia.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA429479
Entities
People
- Irene Andrulius
- Teresa L. Mastracci
Organizations
- Mount Sinai Hospital, Toronto